Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02994108 · ClinicalTrials.gov registry record · NA
txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men
A NA study of Human Papillomavirus, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT02994108 is a NA study of Human Papillomavirus that has completed, run by Northwestern University. The registered enrollment target is 150 participants, below the 26,070-participant average among 12 other Human Papillomavirus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02994108, a NA study of Human Papillomavirus, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Human Papillomavirus (HPV) is a common sexually transmitted infection that can cause cancer (anal, penile, oropharyngeal) and genital warts in men. Due to their sexual practices (e.g., receptive anal intercourse), men who have sex with men (MSM) are at particularly high risk for HPV infection and are disproportionately affected by HPV-related cancers. A safe and effective vaccine is available to prevent HPV infection, yet HPV vaccination rates in the U.S. have been low, particularly among males. To remedy this gap, the goal of this study is to develop and pilot test a text messaging intervention to increase HPV vaccination in young MSM. The study has two specific aims: 1. Develop, iteratively refine, and pre-test messages using a formative research procedure for designing targeted health interventions. The procedure consists of the following steps: 1) conduct online focus groups, an online survey, and in-depth interviews to inform message content, 2) draft initial messages based on focus group findings and pilot data, 3) refine message content and assess acceptability using content advisory teams, 4) conduct internal alpha testing to ensure software functionality, and 5) beta test the protocol. 2. Test the feasibility, acceptability, and preliminary efficacy of the txt2protect (t2p) text messaging intervention in a pilot randomized controlled trial (RCT). To achieve this aim, 460 unvaccinated MSM (ages 18-25) who live in the Chicago metro area will be randomly assigned to the treatment (t2p) or control condition. The treatment condition will receive a culturally appropriate text messaging-based HPV vaccination intervention based on the Information, Motivation, and Behavioral Skills model, whereas the control condition will receive a text messaging-based sexual health intervention that includes basic facts about HPV vaccination readily accessible online. Primary outcome measures include intervention feasibility (e.g., retention in the trial), acceptability (satisf
Conditions Studied
Interventions
- BEHAVIORAL txt2protect
- BEHAVIORAL Sexual Health Control
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2019-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02994108
The ClinicalTrials.gov registry entry for NCT02994108 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,070-participant average among 12 other Human Papillomavirus trials with a reported enrollment target (99% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Papillomavirus appearing as the primary indexed condition, and to 2 interventions - of which txt2protect is the first listed.
NCT02994108 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02994108 about?
NCT02994108 is a clinical study titled "txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men". Human Papillomavirus (HPV) is a common sexually transmitted infection that can cause cancer (anal, penile, oropharyngeal) and genital warts in men. Due to their sexual practices (e.g., receptive anal intercourse), men who have sex with men (MSM) are at particularly high risk for HPV infection and ar...
What is the current status of trial NCT02994108?
This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2018-01-03. Estimated completion is 2019-06-30.
What conditions does trial NCT02994108 study?
This clinical trial studies the following conditions: Human Papillomavirus.
What interventions are being tested in trial NCT02994108?
The interventions under investigation include: txt2protect (BEHAVIORAL), Sexual Health Control (BEHAVIORAL).
Who is sponsoring clinical trial NCT02994108?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02994108 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Provider Recommendation and HPV Vaccination
RECRUITING · NA
-
Video to Promote HPV Vaccination
COMPLETED · NA
-
Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
RECRUITING
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
RECRUITING
-
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.